 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Cabozantinib.
|
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
good results on refractory metastatic renal cell carcinoma
editASCO: Agent Active in Renal Cell Cancer. June 2012 says median progression-free survival of 14.7 months. - Rod57 (talk) 15:17, 10 June 2012 (UTC)
systematic name
editI believe the second N should be N'. Also, "should report interim results mid 2011" needs updating. 69.72.27.176 (talk) 02:26, 19 February 2013 (UTC)
What type/class of C-met inhibitor is it
editShould say here and in c-Met inhibitors. - Rod57 (talk) 02:43, 13 November 2015 (UTC)
- Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist says it is a 'competitive' ATP inhibitor (ie class 1 or 2). What chemical groups does it have ? or how does it bind to c-met ? It looks similar to half of Foretinib which is class II. - Rod57 (talk) 03:12, 13 November 2015 (UTC)
Mechanism of action
editCabozantinib Improves Outcomes Over Erlotinib in Advanced NSCLC says it is also an inhibitor of RET and ROS1. May explain good results in NSCLC. - Rod57 (talk) 12:00, 3 December 2016 (UTC)
in trials for soft-tissue sarcoma
editSoft-tissue sarcoma : Cabozantinib Shows Early Promise in Soft-Tissue Sarcoma says it showed responses in alveolar soft-part sarcoma. - Rod57 (talk) 12:17, 24 November 2017 (UTC)
Interactions
edit"drugs that inhibit these enzymes will make more cabozantinib" - no, they won't; they will make it last longer 96.88.198.77 (talk) 20:45, 16 January 2018 (UTC)
FDA approval in first line clear cell RCC
editOn December 19, 2017, the Food and Drug Administration granted regular approval to cabozantinib for treatment of patients with advanced renal cell carcinoma (RCC). This approval was based on data from CABOSUN (NCT01835158), a randomized, open-label phase 2 multicenter study in 157 patients with intermediate and poor-risk previously untreated RCC. Patients received Cabometyx (n=79) 60 mg orally daily or sunitinib (N=78) 50 mg orally daily (4 weeks on treatment followed by 2 weeks off) until disease progression or unacceptable toxicity. Estimated median progression-free survival (as assessed by blinded independent radiology review committee) for patients taking Cabometyx was 8.6 months (95% CI: 6.8, 14.0) compared with 5.3 months (95% CI: 3.0, 8.2) for patients taking sunitinib (Hazard ratio 0.48; 95% CI: 0.31, 0.74; p=0.0008).
<https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm589842.htm>